Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more
Athira Pharma Inc (ATHA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.174x
Based on the latest financial reports, Athira Pharma Inc (ATHA) has a cash flow conversion efficiency ratio of -0.174x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.67 Million) by net assets ($26.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Athira Pharma Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Athira Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Athira Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athira Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Iex Group NV
AS:IEX
|
0.216x |
|
Freelancer Limited
PINK:FLNCF
|
0.035x |
|
Ashot Ashkelon Industries Ltd
TA:ASHO
|
0.613x |
|
TalkPool AG
ST:TALK
|
0.305x |
|
Axolot Solutions Holding AB
ST:AXOLOT
|
-0.008x |
|
Lewis & Clark Bancorp
PINK:LWCL
|
N/A |
|
Veris Ltd
AU:VRS
|
0.172x |
|
Trailbreaker Resources Ltd
OTCQB:APRAF
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Athira Pharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Athira Pharma Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |